Mr Daan Gijbels, of Dutch descent and Area General Manager for GlaxoSmithKline (Cyprus), is the new president of the Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA). He took over from Jacqueline Anastassiades, General Manager of Merck Sharp & Dohme Cyprus (MSD), who presided over the Association for the past year.
Mr Gijbels has vast experience in the pharmaceutical industry. He joined the GSK team in 2002, after having several consulting roles in other organisations. He held managing positions in London and the Netherlands, and in 2011, he was appointed GSK Area General Manager for Cyprus, Malta and Gibraltar.
“I look forward to co-operating with the rest of the KEFEA members, with the aim of pursuing shared priorities,” said Mr Gijbels, adding that “these priorities include providing Cypriots with quality healthcare and access to new medicines, as well to continue reinforcing KEFEA’s role and image in Cyprus”.
The new KEFEA vice president is Mrs Joanna Kozakou, Operations Manager at the Sanofi company.
KEFEA was founded in in 2006 as the representative body of multinational pharmaceutical companies in Cyprus and is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).
Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA)
The Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) was founded in 2006 as the representative body of multinational pharmaceutical companies in Cyprus. Its members are GSK, Lilly, MSD, Novartis, Pfizer, Sanofi, Janssen and Amgen Hellas altogether employing more than 300 people in Cyprus. It is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). KEFEA’s mission is to provide Cypriots with quality healthcare and access to new medicines. Its objectives are to ensure uninterrupted access to medicines at reasonable prices in the Cyprus market, given the acknowledgement of budgetary constraints, provide scientific educational information on diseases and treatments to healthcare providers, ensure that European objectives regarding high healthcare standards are implemented in the Cyprus market, and comply with a common code of ethical practice.